445 related articles for article (PubMed ID: 17624267)
1. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
2. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil and valsartan inhibit podocyte apoptosis in streptozotocin-induced diabetic rats.
Lv W; Zhang Y; Guan G; Li P; Wang J; Qi D
Pharmacology; 2013; 92(3-4):227-34. PubMed ID: 24158161
[TBL] [Abstract][Full Text] [Related]
4. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
6. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats.
Wu YG; Lin H; Qian H; Zhao M; Qi XM; Wu GZ; Lin ST
Inflamm Res; 2006 May; 55(5):192-9. PubMed ID: 16830106
[TBL] [Abstract][Full Text] [Related]
9. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
10. [Effect of ginsenoside Rgl on the expression of TNF-alpha and MCP-1 in rats with diabetic nephropathy].
Zhang LN; Xie XS; Zuo C; Fan JM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):466-71. PubMed ID: 19627007
[TBL] [Abstract][Full Text] [Related]
11. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
[TBL] [Abstract][Full Text] [Related]
12. Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy.
Wu Y; Dong J; Yuan L; Liang C; Ren K; Zhang W; Fang F; Shen J
Cytokine; 2008 Oct; 44(1):85-91. PubMed ID: 18725182
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
14. [Changes of podocyte ultrastructure and expression of podocyte-associated molecules in rats with diabetic nephropathy].
Chen LP; Zhou QL; Peng WS; Wu XY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):620-5. PubMed ID: 17767053
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
16. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Wang S; Li Y; Huang YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes.
Utimura R; Fujihara CK; Mattar AL; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Jan; 63(1):209-16. PubMed ID: 12472785
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
[TBL] [Abstract][Full Text] [Related]
19. Valsartan inhibited HIF-1α pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats.
Tang L; Yi R; Yang B; Li H; Chen H; Liu Z
Diabetes Res Clin Pract; 2012 Jul; 97(1):125-31. PubMed ID: 22377232
[TBL] [Abstract][Full Text] [Related]
20. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats.
Wu X; Zha D; Xiang G; Zhang B; Xiao SY; Jia R
Cytokine; 2006 Dec; 36(5-6):229-36. PubMed ID: 17337203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
